Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Radiological Investigation II: MRI and Ventilation Perfusion Scan01:30

Radiological Investigation II: MRI and Ventilation Perfusion Scan

107
Description
Magnetic Resonance Imaging (MRI) and Ventilation Perfusion Scans are two radiological investigations that offer detailed diagnostic images of the body, particularly lung structures.
MRI
MRI uses magnetic fields and radiofrequency signals to distinguish between normal and abnormal tissues. This technology provides a more detailed diagnostic image than CT scans, enabling it to characterize pulmonary nodules, stage bronchogenic carcinoma, and evaluate inflammatory activity in...
107
Radiological Investigation III: Pulmonary Angiogram and PET Scan01:13

Radiological Investigation III: Pulmonary Angiogram and PET Scan

89
Radiological investigations are paramount in the diagnosis and management of various pulmonary diseases. Two essential investigations are the Pulmonary Angiogram and the Positron Emission Tomography (PET) Scan.
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...
89

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ARALU - Phase 2, Open-label, Randomized Study to Investigate Safety and Efficacy of Pluvicto Therapy in Patients with Metastatic Hormone-sensitive Prostate Cancer in Addition to Standard of Care Treatment with Nubeqa and ADT.

European urology focus·2026
Same author

Effectiveness and safety of enfortumab vedotin and pembrolizumab in a real-world patient population with urothelial carcinoma: results from a multi-institutional cohort (GUARDIANS).

Cancer immunology, immunotherapy : CII·2026
Same author

Integrating MRI-based tumour staging within the TNM classification system in modern prostate cancer management.

Insights into imaging·2026
Same author

Feasibility of deep learning-accelerated ultrafast T1-weighted VIBE Dixon imaging of the pelvis for screening of metastases in prostate MRI.

European radiology experimental·2026
Same author

Association between traffic-related air pollution and brain morphology, assessing the olfactory pathway as a mediator.

Brain communications·2026
Same author

Reference standards in AI-assisted MRI readings in prostate cancer screening: primetime for benchmarking.

European radiology·2026

Related Experiment Video

Updated: Jun 17, 2025

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy
09:11

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy

Published on: April 9, 2019

21.5K

Update on PI-RADS Version 2.1 Diagnostic Performance Benchmarks for Prostate MRI: Systematic Review and

Benedict Oerther1, Andrea Nedelcu1, Hannes Engel1

  • 1From the Department of Radiology (B.O., A.N., H.E., F.B., M.B.), Institute for Evidence in Medicine (C.S., T.B.), Institute of Medical Biometry and Statistics (G.S.), Department of Urology (A.S., C.G.), and Berta-Ottenstein-Programme (A.S), Faculty of Medicine, University of Freiburg Medical Center, Freiburg, Germany; Department of Radiology & Nuclear Medicine, Erasmus University Medical Center, Rotterdam, the Netherlands (I.G.S); and Department of Diagnostic and Interventional Radiology, Medical Faculty OWL, University of Bielefeld, Klinikum Lippe, Röntgenstrasse 18, 32756 Detmold, Germany (M.E., M.B.).

Radiology
|August 13, 2024
PubMed
Summary

This study provides updated diagnostic accuracy and cancer detection rates for Prostate Imaging Reporting and Data System (PI-RADS) version 2.1. These findings aid in managing clinically significant prostate cancer (csPCa) using MRI.

More Related Videos

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound
06:08

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

Published on: March 21, 2025

147
Use of Magnetic Resonance Imaging and Biopsy Data to Guide Sampling Procedures for Prostate Cancer Biobanking
05:49

Use of Magnetic Resonance Imaging and Biopsy Data to Guide Sampling Procedures for Prostate Cancer Biobanking

Published on: October 10, 2019

6.5K

Related Experiment Videos

Last Updated: Jun 17, 2025

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy
09:11

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy

Published on: April 9, 2019

21.5K
A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound
06:08

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

Published on: March 21, 2025

147
Use of Magnetic Resonance Imaging and Biopsy Data to Guide Sampling Procedures for Prostate Cancer Biobanking
05:49

Use of Magnetic Resonance Imaging and Biopsy Data to Guide Sampling Procedures for Prostate Cancer Biobanking

Published on: October 10, 2019

6.5K

Area of Science:

  • Radiology
  • Oncology
  • Medical Imaging

Background:

  • Prostate MRI utilizes the Prostate Imaging Reporting and Data System (PI-RADS) for clinically significant prostate cancer (csPCa) detection.
  • PI-RADS version 2.1 is the current standard, necessitating updated performance evaluations.
  • A systematic review and meta-analysis infrastructure ensures regular updates on PI-RADS diagnostic performance.

Purpose of the Study:

  • To estimate the diagnostic accuracy of PI-RADS version 2.1 categories for prostate MRI.
  • To determine cancer detection rates (CDRs) associated with each PI-RADS category.
  • To support evidence-based patient management through reliable diagnostic performance data.

Main Methods:

  • Systematic literature search of major databases (PubMed, Embase, Cochrane) and trial registers from March 2019 to August 2022.
  • Inclusion of studies reporting diagnostic accuracy or CDRs for PI-RADS v2.1 with csPCa as the primary outcome.
  • Meta-analysis of lesion- and patient-level data to derive pooled sensitivity, specificity, and CDRs, including subgroup analyses.

Main Results:

  • Meta-analysis of 70 studies (11,686 lesions, 13,330 patients) included.
  • For PI-RADS ≥ 3, summary sensitivity was 96% and specificity 43% (SROC AUC 0.86).
  • For PI-RADS ≥ 4, sensitivity was 89% and specificity 66% (SROC AUC 0.89).
  • Cancer detection rates ranged from 6% for PI-RADS 1 to 84% for PI-RADS 5.

Conclusions:

  • Provides current estimates of diagnostic accuracy and cancer detection rates for PI-RADS version 2.1.
  • Offers benchmarks for quality assessment in prostate MRI interpretation.
  • Aids in refining patient management strategies for prostate cancer based on MRI findings.